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Amniotic fluid embolism: an Australian-
New Zealand population-based study
Nolan McDonnell1,11,12*, Marian Knight2, Michael J. Peek3, David Ellwood4,5, Caroline S. E. Homer6,
Claire McLintock7, Geraldine Vaughan6, Wendy Pollock8,9, Zhuoyang Li6, Nasrin Javid6, Elizabeth Sullivan6,10 and
on behalf of the Australasian Maternity Outcomes Surveillance System (AMOSS)
Abstract
Background: Amniotic fluid embolism (AFE) is a major cause of direct maternal mortality in Australia and New
Zealand. There has been no national population study of AFE in either country. The aim of this study was to estimate
the incidence of amniotic fluid embolism in Australia and New Zealand and to describe risk factors, management, and
perinatal outcomes.
Methods: A population-based descriptive study using the Australasian Maternity Outcomes Surveillance System (AMOSS)
carried out in 263 eligible sites (>50 births per year) covering an estimated 96 % of women giving birth in Australia and
all 24 New Zealand maternity units (100 % of women giving birth in hospitals) between January 1 2010-December 31
2011. A case of AFE was defined either as a clinical diagnosis (acute hypotension or cardiac arrest, acute hypoxia and
coagulopathy in the absence of any other potential explanation for the symptoms and signs observed) or as a post
mortem diagnosis (presence of fetal squames/debris in the pulmonary circulation).
Results: Thirty-three cases of AFE were reported from an estimated cohort of 613,731women giving birth, with an
estimated incidence of 5.4 cases per 100 000 women giving birth (95 % CI 3.5 to 7.2 per 100 000). Two (6 %) events
occurred at home whilst 46 % (n = 15) occurred in the birth suite and 46 % (n = 15) in the operating theatre (location
not reported in one case). Fourteen women (42 %) underwent either an induction or augmentation of labour and 22
(67 %) underwent a caesarean section. Eight women (24 %) conceived using assisted reproduction technology.
Thirteen (42 %) women required cardiopulmonary resuscitation, 18 % (n = 6) had a hysterectomy and 85 % (n = 28)
received a transfusion of blood or blood products. Twenty (61 %) were admitted to an Intensive Care Unit (ICU), eight
(24 %) were admitted to a High Dependency Unit (HDU) and seven (21 %) were transferred to another hospital for
further management. Five woman died (case fatality rate 15 %) giving an estimated maternal mortality rate due to AFE
of 0.8 per 100 000 women giving birth (95 % CI 0.1 % to 1.5 %). There were two deaths among 36 infants.
Conclusions: A coordinated emergency response requiring resource intense multi-disciplinary input is required in the
management of women with AFE. Although the case fatality rate is lower than in previously published studies, high
rates of hysterectomy, resuscitation, and admission to higher care settings reflect the significant morbidity associated
with AFE. Active, ongoing surveillance to document the risk factors and short and long-term outcomes of women and
their babies following AFE may be helpful to guide best practice, management, counselling and service planning.
A potential link between AFE and assisted reproductive technology warrants further investigation.
Keywords: Amniotic fluid embolism, Maternal mortality, Postpartum hemorrhage, Blood transfusion, Reproductive
techniques, Assisted
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Background
Amniotic fluid embolism (AFE) is a rare and incompletely
understood condition that is unique to pregnancy. The
condition is characterised by the sudden onset of maternal
compromise generally involving the cardio-respiratory
and haematological systems, which can rapidly progress to
cardiac arrest and profound coagulopathy leading to death
[1]. Despite its rarity, AFE is now a leading cause of mater-
nal mortality in a number of countries, and in Australia
[2] and New Zealand [3] it is the leading cause of direct
maternal mortality. The rarity of the condition and the
lack of a reliable animal model hamper efforts to study the
condition in greater depth, hence case registries and the
publication of case reports are important in the advance-
ment of knowledge of AFE. The Australasian Maternity
Outcomes Surveillance System (AMOSS) was established
across maternity units in Australia and New Zealand in
2009 in order to study rare and serious disorders of
pregnancy [4, 5]. The aim of this paper was to estimate
the incidence of AFE in Australia and New Zealand and
to describe risk factors, management, and outcomes for
women from the first two years of AMOSS surveillance
into AFE.
Methods
AMOSS is a bi-national surveillance and research system
that utilizes a web based prospective clinical audit of a
range of rare disorders of pregnancy. Ninety four percent
of eligible Australian maternity units (n = 263/279) cover-
ing an estimated 96 % of women giving birth in hospital
and all 24 New Zealand maternity units (100 % of hospital
births) participate in AMOSS, with equal representation
of public and private hospital sites.
A staggered implementation of AMOSS occurred as eth-
ics, governance and site approvals were granted between
2008-2011 [4]. AMOSS sites were eligible for participation
across Australia and New Zealand if they had over 50
births per year. At the commencement of surveillance in
January 2010, 107 (37 %) of 291 sites were active, covering
59 % of births across Australia and New Zealand. This rose
to 260 sites covering 90 % of births by December 2010 and
to 291 of 301 eligible sites by December 2011 [5].
Women with AFE were identified by AMOSS data col-
lectors (predominantly midwives, obstetricians, anaesthe-
tists and health information managers) in maternity units
through a monthly active negative surveillance system
between January 1, 2010 and December 31, 2011. The
average monthly response rate for active surveillance was
88 % during the study period. After data collectors notified
a case, they were then prompted to confirm case eligibility
by responding to a standardised case definition. A case of
AFE was defined either as a clinical diagnosis (acute
hypotension or cardiac arrest, acute hypoxia and coagu-
lopathy in the absence of any other potential explanation
for the symptoms and signs observed) or as a post mor-
tem diagnosis (presence of fetal squames/debris in the
pulmonary circulation). Sites were provided with clear
guidance on the case definition and reporting criteria. In
cases with any uncertainty over the diagnosis, they were
able to contact the investigating team for guidance prior
to submitting a case report.
Data were collected using two secure, web-based clinical
data collection forms. The first form captured data on
baseline demographic and pregnancy factors, obstetric
interventions and perinatal outcomes and was utilised for
all conditions being studied by AMOSS. The second form
was a case-specific questionnaire, which included the
location of the woman’s initial presentation/collapse; the
most prominent initial presenting feature; other associated
features; therapy required (including cardio-pulmonary
resuscitation (CPR), intubation/ventilation, admission to
ICU or HDU, blood and blood products); results of rele-
vant investigations and maternal and neonatal outcomes.
Data collectors were contacted regarding missing data or
where data were not consistent with expected values to
ensure validation. Free-text responses to questions regard-
ing medical or obstetric morbidity were classified accord-
ing to ICD-10-AM [6].
Ethics and governance processes for AMOSS ranged
from a single application, multi-region ethics approval
(MEC/09/73/EXP) in New Zealand, to multiple Human
Research Ethics Committees for individual sites across
Australia. Over 46 full ⁄ expedited ethics applications, 131
site governance applications and 136 letters of support re-
quests were made over a 33 month period in Australia [4].
The current list of participating sites is listed in AMOSS
newsletters [7]. Informed consent from women or their
next of kin to participate in AMOSS was not required from
the lead Human Ethics Committees (the New South Wales
Population and Health Research Ethics Committee and the
University of New South Wales Human Research Ethics
Committee) or as part of the individual site approval
processes.
Statistical analyses
Incidence rates and maternal mortality ratios were calcu-
lated with 95 % confidence intervals (CI). Rates were cal-
culated using denominators estimated from data provided
by participating maternity sites on women giving birth
(defined as the birth of one or more live or stillborn
infants of at least 400 g birthweight, or at least 20 weeks’
gestation) in Australia and New Zealand. Denominator
populations for Australia and New Zealand were esti-
mated using the number of births in participating mater-
nity sites between January 1 2010-December 31 2011. To
address the staggered implementation of AMOSS, when
defining birth rates, Australian birth denominators were
adjusted for each hospital according to the number of days
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active as an AMOSS participating site. The incidence of
AFE was calculated per 100,000 women giving birth.
Results
Over the study period there were 33 reported cases of
AFE associated with five maternal deaths (case fatality rate
of 15 %). The five women who died were diagnosed on the
basis of clinical criteria; three women who died did not
have a post-mortem examination, and in the remaining
two there was no evidence of fetal debris in the maternal
circulation. Over the corresponding period in Australia
and New Zealand there were 613,731 women giving birth
in participating maternity sites, giving an incidence of 1 in
18,598, or 5.4 per 100,000 women giving birth (95 % CI
3.5–7.2 per 100,000) and a maternal mortality of 0.8 per
100,000 women giving birth (95 % CI 0.1-1.5 per 100,000).
The median age of women was 35 years (range 16–43)
(Table 1). Eight women (24 %) had undergone a caesarean
section in a previous pregnancy, five (15 %) had been
diagnosed with a placenta praevia during the index
pregnancy related to the AFE and four women (12 %) had
episodes of antepartum haemorrhage. The index preg-
nancy was a multiple gestation in three women (9 %) and
polyhydramnios was diagnosed in two women (6 %).
A total of 14 women (42 %) underwent either an induc-
tion or augmentation of labour [8 (24 %) induction only, 2
(6 %) augmentation only and 4 (12 %) both induction and
augmentation] (Table 2). Fifteen events (46 %) occurred in
the birth suite whilst 15 (46 %) occurred in the operating
theatre, two events (6 %) occurred at home and in one
woman the location was unknown (Table 3). One third
(33 %) had a normal vaginal birth with the remainder
having a caesarean section (67 %). The onset of the AFE
episode was recorded as having occurred within 5 min be-
fore or after the birth in 48 % of women whilst overall
41 % occurred prior to birth and 57 % occurred post-
partum (Table 3). In the women who were still pregnant
at the time of the event, the maximum interval from the
onset of the episode until birth was 89 min, whilst the
latest presentation was recorded 240 min post-partum.
Five women presented 30 min or more after delivery.
The most commonly reported initial presenting features
were premonitory symptoms (27 %), hypotension (21 %),
shortness of breath (15 %) and acute fetal compromise
(15 %) (Table 3). Associated features included maternal
haemorrhage (79 %), hypotension (76 %) and coagulopa-
thy (73 %) (Table 3).
Cardiopulmonary resuscitation was required for 42 % of
women (Table 4). Blood products were administered to
the majority of women (Table 4) and included red cells
Table 1 Characteristics of women with Amniotic Fluid
Embolism, Australia and New Zealand 2010–2011
Characteristic N (%)
Age <25 2 (6 %)
25–29 6 (18 %)
30–34 8 (24 %)
>35 17 (52 %)
Gravidity 1 14 (42 %)
2 6 (18 %)
3 or more 13 (40 %)
Parity 0 17 (52 %)
1 7 (21 %)
2 or more 9 (27 %)
Previous Caesarean section 8 (24 %)
Assisted Conception 8 (24 %)
Multiple Pregnancy 3 (9 %)
Gestational age at birth 20 to 27 weeks 1 (3 %)
28 to 31 weeks 1 (3 %)
32 to 36 weeks 7 (21 %)
37 to 41 weeks 24 (73 %)
Placenta Praevia 5 (15 %)
Antepartum Haemorrhage 4 (12 %)
Current smoker 3 (9 %)
BMI >35 2 (6 %)
Pre-eclampsia 2 (6 %)
Polyhydramnios 2 (6 %)
Gestational diabetes 2 (6 %)
Other hypertensive disorder 2 (6 %)
BMI: Body mass index
Data are number (percentage)
Table 2 Labour and mode of birth of women with Amniotic
Fluid Embolism, Australia and New Zealand 2010–2011
N (%)
Induction of labour Yes 12 (36 %)
No 9 (27 %)
N/A (no labour) 12 (36 %)
Augmentation of labour Yes 6 (18 %)
No 15 (46 %)
N/A (no labour) 12 (36 %)
Meconium stained liquor Fresh 2 (6 %)
None 30(91 %)
Unknown 1 (3 %)
Method of birth
Vaginal birth 11 (33 %)
Caesarean section 22 (67 %)
Elective 6 (18 %)
Non elective 8 (24 %)
Not recorded 8 (24 %)
Data are number (percentage)
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(85 %), cryoprecipitate (73 %), fresh frozen plasma (73 %)
and platelets (58 %). Six women (18 %) had a hysterectomy
to control bleeding. Laboratory markers indicating a signifi-
cant coagulopathy were frequently recorded with a fibrino-
gen of <2 g/dl in 64 %, a platelet count of <100 × 109/L in
61 % and an INR >1.5 in 48 %. Twenty (61 %) women were
admitted to ICU, eight (24 %) women to an obstetric HDU,
and three women (9 %) died before being transferred to
ICU or HDU for admission. Seven women (21 %) required
transfer to another hospital for further management.
Of the five reported maternal deaths secondary to
AFE, three of the women were born outside of Australia
or New Zealand; the age range was between 23 and
35 years and there was one twin pregnancy. Four women
laboured, of which one had an induction of labour, one
was augmented and one was both induced and aug-
mented. Four women underwent an unplanned caesarean
section and one had a vacuum extraction. The AFE first
manifested between 5 min prior to the birth up until
18 min post-partum and the time from the onset of the
episode until the time of death ranged from between 35
and 108 min in four women, with one woman surviving in
an ICU environment for approximately three weeks.
The 33 women gave birth to 36 babies including one
stillbirth prior to the onset of labour and one neonatal
death (neonatal mortality of 2.7 %) of an infant born with
a congenital abnormality that was not compatible with life.
Twenty three of the babies were male (64 %) and 25
(69 %) required admission to a Neonatal Intensive Care
Unit (NICU). Fourteen babies were unborn at the onset of
the AFE episode; compared to babies born prior to the
onset of the AFE episode they had lower 5 min Apgar
scores (Apgar score <7 in 67 % versus 0 %), a higher NICU
admission rate (100 % versus 53 %) and a higher require-
ment for intubation and ventilation (n = 7/14 (50 %) versus
n = 1/16 (6 %)).
Discussion
This study represents the first prospectively collected data
on women with both fatal and non-fatal AFE in the
Australian and New Zealand population. In total, 33 cases
of AFE were reported, giving an incidence of 5.4 per
100,000 women giving birth. There were five deaths
secondary to AFE, a maternal mortality of 0.8 per 100,000
women giving birth. Although described as a rare condi-
tion, AFE has long been established as the leading cause of
direct maternal mortality in Australia [2] as well as in
New Zealand [3], occurring more frequently than mater-
nal deaths from hypertensive disorders, sepsis, obstetric
haemorrhage and venous thromboembolism. Internation-
ally AFE ranks as a leading cause of maternal mortality in
many developed countries, and in the UK triennial report
AFE was ranked as the fourth leading cause of direct ma-
ternal mortality [8], with a comparable maternal mortality
to that reported in this study of 0.57 per 100,000 women.
AFE is a poorly understood condition and because of its
rare and unpredictable nature, combined with the lack of
an appropriate animal model to study the condition, the
use of case registries and case series is required to further
advance knowledge of the condition.
The incidence of AFE reported in our study appears
higher than those reported from similarly high resource
countries [9] but consistent with previously reported
data from Australia [9]. The UK Obstetric Surveillance
System (UKOSS) [10], using similar methodology, re-
ported an incidence of AFE of 2.0 per 100,000 deliveries
compared to the incidence of 5.5 per 100,000 reported
here. A number of factors may influence the reported in-
cidence of AFE. Firstly, as there is no specific diagnostic
Table 3 Features of Amniotic Fluid Embolism at presentation,
Australia and New Zealand 2010-2011
Number of women
experiencing feature (%)
Location of onset Home 2 (6 %)
Theatre 15 (46 %)
Birth Suite 15 (46 %)
Not recorded 1 (3 %)
Time point at
onset of collapse
Pre-labour 5 (15 %)
First stage of labour 4 (12 %)
Second stage of labour 4 (12 %)
Post partum 17 (52 %)
Unknown/Not recorded 3 (9 %)
Initial presenting
feature
Premonitory symptoms 9 (27 %)
Hypotension 7 (21 %)
Shortness of breath 5 (15 %)
Acute fetal compromise 5 (15 %)
Maternal haemorrhage 3 (9 %)
Coagulopathy 3 (9 %)
Cardiac arrest 2 (6 %)
Abnormal cardiac rhythm 2 (6 %)
Seizure(s) 1 (3 %)
Associated features Maternal haemorrhage 26 (79 %)
Hypotension 25 (76 %)
Coagulopathy 24 (73 %)
Premonitory symptoms 14 (42 %)
Cardiac arrest 13 (39 %)
Shortness of breath 12 (36 %)
Acute fetal compromise 9 (27 %)
Abnormal cardiac rhythm 8 (24 %)
Seizure(s) 3 (9 %)
Data are number (percentage)
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test for AFE, it remains a diagnosis of exclusion [11].
Even though there are generally consistent diagnostic
criteria for AFE across the major registries, whether a
woman is reported as experiencing AFE may still come
down to clinical judgement. This is likely to result in
both false positive and false negative cases occurring. In
addition, with the increasing recognition of AFE as a po-
tential cause of maternal compromise, it is likely that
less severe cases are now being included in registries
and surveillance systems [12].
How AFE cases are identified may also influence the
reported incidence of the condition. Knight et al. re-
cently showed that using population-based data to deter-
mine the incidence of AFE resulted in more than double
the number of cases that were identified with a specific
validated case identification system [9]. When additional
criteria were used to exclude potential false positive
cases, data more consistent with case validation systems
were obtained. Currently, as has been previously recom-
mended [9], the ideal approach to improve the accuracy
of case identification may be case notification followed
by a detailed review of the medical record by a recog-
nised expert.
A potential limitation of this study is the impact of the
incremental participation by Australian maternity units
in AMOSS during the initial study period. The imple-
mentation of AMOSS across Australian units was stag-
gered as governance and site approvals were granted
between 2008 and 2011 [4]. This was necessary as there
was no consistent process for ethical approval across all
maternity units in Australia, compared to NZ which has
a streamlined approval system for multicentre research
[13]. In January 2010, at the commencement of surveil-
lance, 107 (37 %) of 291 sites were active, covering 59 %
of births across Australia and New Zealand rising to
291(97 %) of 301 eligible sites by December 2011. In
addition, this study focused on the initial presentation
and management of the AFE. Longer term data in rela-
tion to outcomes such as neurological deficits was not
able to be captured. With the de-identified nature of the
data entry there was no ability to cross reference the ma-
ternal deaths that occurred with the currently available
maternal mortality reporting systems in Australia and
New Zealand. With the rare nature of the condition,
cases which may have been missed because of presenta-
tion to a non obstetric hospital may have significant
impact on the incidence and outcome data.
The results presented in this study confirm that man-
agement of women with AFE requires significant utilisa-
tion of resources such as operating theatre, transfusion
Table 4 Management of women with Amniotic Fluid Embolism, Australia and New Zealand 2010-2011
Number of women (%)
Median (IQR)
Transfer to other hospital site 7 (21 %)
Hysterectomy 6 (18 %)
Plasmaphoresis 2 (6 %)
Recombinant Factor VIIa 8 (24 %)
Intubation/Ventilation 14 (42 %)
ECMO 0 (0 %)
CPR 14 (42 %)
Blood and blood products Yes 28 (85 %)
Red Cells 28 (85 %) 9.5 (5.3–13.8)
Fresh Frozen Plasma 24 (73 %) 6.0 (4–8.75)
Cyroprecipitate 24 (73 %) 9.0 (4.3–20)
Platelets 19 (58 %) 3.0 (2.0–4.0)
Blood Results (Worst recorded) Haemoglobin <7 g/dl 17 (52 %)
Fibrinogen <2 g/dl 21 (64 %)
Platelets <100 109/L 20 (61 %)
INR >1.5 16 (48 %)
Level of care required Required admission to ICU 20 (61 %)
Required admission to HDU only 8 (24 %)
Died prior to accessing ICU/HDU 3 (9 %)
Did not require ICU or HDU care 1 (3 %)
ECMO Extracorporeal Membrane Oxygenation, CPR Cardiopulmonary resuscitation, ICU Intensive Care Unit, HDU High Dependency Unit
Data are number (percentage) or median (interquartile range (25 %–75 %))
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medicine and intensive care services. AFE is unpredictable
and may be associated with rapid maternal compromise.
Health and maternity care providers, either in the com-
munity or hospital setting, must be aware of the key differ-
ences in the resuscitation of pregnant compared to non
pregnant women [14]. Particular emphasis on the need for
relief of aortocaval compression and the role of peri-
mortem caesarean section in maternal resuscitation is
important [15]. Previous maternal mortality reports have
shown that maternal resuscitation is often substandard
and emphasise the importance of training courses for staff
in obstetric emergencies [8, 16]. Of importance, a collapse
secondary to AFE may occur in any delivery setting,
reinforcing the need for all health care providers who may
care for pregnant women to be adequately trained in their
initial resuscitation. It is encouraging that in this study,
women who did suffer a cardiac arrest still had a high
survival rate. In total 14 women underwent CPR for a
presumed cardiac arrest and at least 9 (64 %) of these
women survived. The high survival from cardiac arrest is
likely to be multifactorial in nature and a reflection of the
comparatively younger age compared to other patients
who may suffer a cardiac arrest, lack of underlying co-
morbidities such as ischaemic heart disease, increased
physiological reserve associated with pregnancy in addition
to the presentation likely occurring in environments with
close monitoring and access to emergency care.
In women who survive the initial cardiopulmonary
compromise, management of coagulopathy and major
obstetric haemorrhage assume critical importance. Peri-
partum hysterectomy is frequently required to control
bleeding and a significant number of women will require
admission to intensive or high dependency care services,
as well as increased levels of care for their newborn. Not
all centres that care for pregnant women may have
onsite access to these facilities, especially in rural or re-
mote areas and this study highlights the importance for
all centres to have procedures to ensure timely transfer
of women and their babies to appropriate centres.
The mortality associated with AFE was initially reported
to be very high, with case fatality rates of 67-86 % reported
in some of the first case series of AFE [17, 18]. The case
fatality rate of 15 % reported here is consistent with previ-
ous reports from Australia [9], the UK [10], Netherlands
[19], Canada [20] and the USA [21]. Factors that may
contribute to a lower case fatality rates include an improved
awareness of the condition so that women with less severe
AFE are now included in registries, in addition to improve-
ments in the resuscitation of pregnant women and ad-
vances in intensive care. The cornerstone of management
is early recognition of the condition with prompt support-
ive measures. Premonitory symptoms, shortness of breath,
hypotension and acute fetal compromise are consistently
the earliest indications of AFE and should not be ignored.
A number of risk factors have been previously identified
for AFE including advanced maternal age, polyhydramnios,
multiple gestation, placental abnormalities and caesarean
section [9, 21]. Whilst the numbers reported in this study
are comparatively small, these risk factors would appear to
be consistent when the women reported in this study are
compared to the overall maternity population in Australia
over a similar time period [22]. In a group of control
women identified from other AMOSS studies, 24.5 % were
aged 35 or over, 2.4 % had a multiple pregnancy and
19.3 % a previous caesarean delivery [23]. Induction and/or
augmentation of labour has previously been suggested as a
potential risk factor for AFE [9, 20, 24], in this study 36 %
of women were classified as having an induction of labour
whilst over a similar period of time population based
Australian data showed that the overall induction rate was
26 % [22]. Whilst this supports the potential link between
AFE and induction of labour, the small numbers reported
here mean that this should be interpreted with caution.
There were a high number of women who had had assisted
conception in our study (8/33, 24 % vs national figures of
3.8 % [22]), to our knowledge the use of assisted reproduct-
ive technology has not been previously examined as a
potential risk factor for AFE. Whilst the higher incidence
may potentially be explained by the relationship to other
established risk factors such as advanced maternal
age, given the potential immune mediated theories for
the pathogenesis of AFE this finding warrants further
investigation.
The neonatal outcomes reported in this study compare
favourably to previously reported data and are notable for
a low stillbirth and neonatal death rate. A number of stud-
ies have reported high stillbirth and neonatal death rates
[9, 19], whilst other studies have reported few or no neo-
natal deaths [20]. This is a welcome finding even noting
the limitation of the small number of cases. This study
highlights that the neonatal outcomes associated with AFE
are likely related to the birth status of the neonate at the
time of the onset of the AFE episode. Those babies who
were born prior to the onset of the episode were born in
much better condition then those born after the onset of
the AFE, with better 5 min Apgar scores and less need for
NICU admission and invasive ventilation. Fetal heart rate
abnormalities are a common presenting feature of AFE,
highlighting the sensitivity of the fetus to any compromise
of the maternal state. Appropriate resuscitation of the
mother, including the performance of a peri-mortem cae-
sarean section if indicated, is an important component of
the management process.
Conclusion
This study shows that the majority of women with AFE
suffer significant morbidity but survive and highlights
the importance a heightened awareness of this condition
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by clinical staff caring for pregnant women along with the
need to maintain competence in resuscitation. Ongoing
surveillance to document the risk factors and short and
long-term outcomes of women and their babies following
AFE may be helpful to guide best practice, management,
counselling and service planning. A potential link between
AFE and assisted reproductive technology warrants fur-
ther investigation.
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